Comparing Pembrolizumab and Sintilimab for Advanced Lung Cancer
Author Information
Author(s): Xia Zhengzheng, Hong Juan, Yu Xiangyang, Ran Yuhua, Xie Huali, Zhou Ziyuan, Zuo Jing, Chen Tujia, Meng Jun, Yang Jun
Primary Institution: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Hypothesis
Do pembrolizumab and sintilimab have significantly different effects on patients with advanced non-small cell lung cancer (NSCLC)?
Conclusion
Sintilimab and pembrolizumab show similar effectiveness in treating advanced NSCLC, but sintilimab may have a better safety profile.
Supporting Evidence
- Median progression-free survival was 8.68 months for sintilimab and 9.46 months for pembrolizumab.
- Objective response rate was 30.2% for pembrolizumab and 41.3% for sintilimab.
- Disease control rate was 84.1% for pembrolizumab and 88.9% for sintilimab.
- Grade 3 or 4 treatment-related adverse events were higher in the pembrolizumab group (42.9%) compared to sintilimab (33.3%).
Takeaway
This study looked at two cancer treatments and found that they work about the same, but one might be safer than the other.
Methodology
A retrospective multicenter cohort study with propensity-score matching analysis comparing the effectiveness and safety of pembrolizumab and sintilimab.
Potential Biases
Potential biases due to unmeasured confounders like baseline health status and lifestyle factors.
Limitations
The study is retrospective, and unobserved factors may have influenced outcomes; it also involved only Chinese patients from two hospitals.
Participant Demographics
Patients aged 18 to 90 years with advanced NSCLC, including both male and female participants.
Statistical Information
P-Value
0.043
Confidence Interval
95% CI 0.466–1.583
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website